A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.

по Halaschek-Wiener, J., Wacheck, V., Schlagbauer-Wadl, H., Wolff, K., Kloog, Y., Jansen, B.
Опубликовано 2000

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells

по Wacheck, V, Selzer, E, Günsberg, P, Lucas, T, Meyer, H, Thallinger, C, Monia, B P, Jansen, B
Опубликовано 2003

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

по Cejka, D, Kuntner, C, Preusser, M, Fritzer-Szekeres, M, Fueger, B J, Strommer, S, Werzowa, J, Fuereder, T, Wanek, T, Zsebedics, M, Mueller, M, Langer, O, Wacheck, V
Опубликовано 2009

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

по Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr W, Valent P
Опубликовано 2011-05-01